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Abstract
Background: Spartin protein is involved in degradation of epidermal growth factor receptor and turnover of lipid
droplets and a lack of expression of this protein is responsible for hereditary spastic paraplegia type 20 (SPG20).
Spartin is a multifunctional protein that associates with many cellular organelles, including lipid droplets. Recent
studies showed that spartin interacts with E3 ubiquitin ligases that belong to the neural precursor cell-expressed
developmentally downregulated gene (Nedd4) family, including atrophin-1-interacting protein 4 (AIP4/ITCH).
However, the biological importance of the spartin-AIP4 interaction remains unknown.
Results: In this study, we show that spartin is not a substrate for AIP4 activity and that spartin’s binding to AIP4
significantly increases self-ubiquitination of this E3 ligase, indicating that spartin disrupts the AIP4 autoinhibitory
intramolecular interaction. Correspondingly, spartin has a seven times higher binding affinity to the WW region of
AIP4 than the binding of the WW region has to the catalytic homologues of the E6-associated protein C-terminus
(HECT) domain, as measured by enzyme-linked immunosorbent assay. We also show that spartin recruits AIP4 to
lipid droplets and promotes ubiquitination of lipid droplet-associated protein, adipophilin, which regulates turnover
of lipid droplets.
Conclusions: Our findings demonstrate that spartin acts as an adaptor protein that activates and recruits AIP4 E3
ubiquitin ligase to lipid droplets and by this means regulates the level of ubiquitination of adipophilin and
potentially other lipid-associated proteins. We propose that this is one of the mechanisms by which spartin
regulates lipid droplet turnover and might contribute to the pathology of SPG20.
Background
The hereditary spastic paraplegias (HSPs) are inherited
neurological disorders characterized by progressive spas-
ticity and muscle weakness in the lower limbs [1].
Troyer syndrome is an autosomal recessive HSP caused
b yaf r a m e s h i f tm u t a t i o ni nt h es p a r t i ng e n e( SPG20)
[2], resulting in a loss of expression of the mutated
protein [3].
Spartin harbors a microtubule-interacting and traffick-
ing (MIT) domain and a plant-senescence domain at its
N-terminus and C-terminus, respectively [4]. The latter
domain was suggested to be responsible for spartin’s
association with lipid droplets in cells incubated with
oleic acid [5]. Spartin has a multifunctional role in cells
as evidenced by its association with membranes of sev-
eral cellular organelles [5,6] and its interaction with
many binding partners [7]. Thus far is it known that
spartin is important in the trafficking of epidermal
growth factor receptors [6,8] and in the turnover of
lipid droplets [5]. Lipid droplets contain a neutral lipid
core surrounded by a monolayer of polar lipids. The
membrane layer of the lipid droplet has two major
groups of proteins: enzymes important in lipid meta-
bolism and the perilipin, adipophilin, and 47-kDa tail
interacting protein (PAT) family of peripheral mem-
brane proteins involved in stabilizing lipid droplets [9].
Spartin is known to be ubiquitinated and interacts
with several E3 ubiquitin ligases that harbor a homolo-
gous to E6-associated protein C-terminus (HECT)
domain. These ligases belong to the neural precursor
cell-expressed developmentally downregulated gene
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tein 4 (AIP4) [8,10] and atrophin-1-interacting protein
5, also known as the WW domain-containing E3 ubiqui-
tin protein ligase 1 (AIP5/WWP1) [5,8]. Although pre-
vious studies have shown that AIP5 is responsible for
ubiquitination of spartin and removes spartin from the
lipid droplets [5], a recent report demonstrated that
depletion of AIP4 and AIP5 had no effect on spartin’s
ubiquitination [8]. Furthermore, the importance of the
interaction between spartin and E3 ubiquitin ligases
with the HECT domain remains unknown.
In this study, we provide evidence that spartin is not
ubiquitinated by AIP4; rather, spartin acts as an adaptor
protein that, through binding to AIP4, increases the
enzymatic activity of this E3 ligase by releasing AIP4
from its autoinhibited state. We also demonstrate that
spartin recruits AIP4 to lipid droplets and is a necessary
adaptor protein for polyubiquitination of adipophilin on
lipid droplets. This might be one of the mechanisms by
which spartin regulates the turnover of lipid droplets.
Results
Ubiquitination levels of spartin are not altered by AIP4
Previous studies showed that spartin interacts with AIP2
(also known as WW domain-containing protein 2
(WWP2)), AIP4, and AIP5 through its PPAY motif
[5,8]. However, there is a discrepancy between previous
studies: one found that spartin is a substrate of AIP4
and AIP5 E3 ligases [5], but another found that spartin
is not a substrate of those ligases [8]. To resolve this
discrepancy, we used an in vivo ubiquitination assay to
investigate the ubiquitination status of spartin in cells
overexpressing ubiquitin together with either wild-type
or enzymatically inactive AIP4. Specifically, we exam-
ined the conjugation of hemagglutinin (HA)-tagged
ubiquitin into Myc-spartin that had been immunopreci-
pitated from HeLa cells cotransfected with ubiquitin and
spartin together with either Flag-AIP4 or Flag-
AIP4C830A.
Before immunoprecipitation, cell lysates were boiled in
sodium dodecyl sulfate (SDS) to eliminate proteins that
could coprecipitate with spartin. Immunoblots showed
that, in the presence of wild-type AIP4 or catalytically
inactive AIP4C830A, the ubiquitination levels of over-
expressed spartin were similar (Figure 1a). As we pre-
viously shown [6], spartin was monoubiquitinated and
polyubiquitinated when overexpressed with exogenous
ubiquitin. However, the polyubiquitination of spartin
does not result in its increased degradation by protea-
somes (data not shown).
The interaction between spartin and AIP4 or AIP5 is
mediated by spartin’s PPAY motif. When the PPAY motif
within spartin was mutated to PAAA, it abrogated the
interaction with AIP5 and AIP4 ([5,8] and this study). One
report found that this mutation resulted in the loss of ubi-
quitination of spartin [5], but Edwards and colleagues [8]
reported that this mutation had no effect on the levels
of spartin’s ubiquitination. To resolve these contradictory
results, we further examined the ubiquitination levels of
spartin after preventing its binding to AIP4 by mutating
the PPAY motif or using the fragment of spartin depleted
of its N-terminus containing the PPAY motif. We over-
expressed HA-wild-type spartin, HA-mutant spartin PY/
AA (in which PPAY motif was mutated to PAAA) or HA-
tagged spartin fragment 211-666 (which lacks the PPAY
motif) together with Flag-ubiquitin in HeLa cells. As
shown in Figure 1b, overexpressed spartin PY/AA and the
spartin fragment (211-666) were both monoubiquitinated
and polyubiquitinated to the same extent as the wild-type
spartin. Neither overexpressed spartin PY/AA nor the
spartin fragment (211-666) interacted with AIP4
(Figure 1c). We summarized the association of different
spartin constructs with AIP4 and their ubiquitination sta-
tus in Figure 1d. Overall, our results indicate that the
levels of spartin’s ubiquitination are not affected by its
association with AIP4.
Spartin recruits AIP4 to endogenous lipid droplets
Although spartin interacts with AIP4, it is still ubiquiti-
nated in the presence of an enzymatically inactive
mutant of AIP4, suggesting that spartin is not a sub-
strate of AIP4. Those data prompted us to investigate
whether spartin acts as an adaptor protein that alters
the localization of AIP4 in the cell. We used immuno-
fluorescence to examine the subcellular localization of
overexpressed AIP4 alone or together with the wild-type
spartin or mutant spartin PY/AA, which does not bind
to AIP4. We found that HA-spartin (Figure 2a, 1) was
localized in the cytoplasm and associated with endogen-
ous lipid droplets (Figure 2a, 4) in nearly all transfected
cells (Figure 2e). In contrast, overexpressed Flag-AIP4
(Figure 2b, 2) did not associate with lipid droplets in
any examined cells (Figure 2b, 4). However, when HA-
spartin and Flag-AIP4 were cotransfected, Flag-AIP4
was recruited to endogenous lipid droplets by HA-wild-
type spartin in nearly all cotransfected cells (Figure 2c).
Cells coexpressing HA-mutant spartin PY/AA and Flag-
AIP4 showed diffuse staining of AIP4 (Figure 2d, 2) but
no colocalization with the mutant spartin (Figure 2d, 1)
in lipid droplets (Figure 2d, 3) in any cotransfected cells.
However, HA-mutant spartin PY/AA (Figure 2d, 1)
associated with lipid droplets (Figure 2d, 4) similarly to
HA-wild-type spartin (Figure 2c, 1 and 2d, 4).
W ea l s of o u n dt h a tH A - w i l d - t y p es p a r t i nb u tn o t
mutant spartin PY/AA sequestered AIP2 to the lipid
droplets (Additional file 1). These results reveal that
spartin is an adaptor protein that recruits AIP2 and
AIP4 to the lipid droplets.
Hooper et al. BMC Biology 2010, 8:72
http://www.biomedcentral.com/1741-7007/8/72
Page 2 of 11Spartin increases the activity of AIP4 in vivo and in vitro
To further investigate the role of spartin as an adaptor
protein in binding with AIP4, we examined whether, in
addition to recruiting AIP4 to lipid droplets, spartin also
enhances its enzymatic activity. It has been shown that,
because of the presence of the catalytic HECT domain,
the level of self-ubiquitination of AIP4 is a good mea-
sure of its enzymatic activity [11,12].
We examined the levels of AIP4 ubiquitination
in HeLa cells in which Flag-AIP4 was cotransfected
with HA-ubiquitin and either Myc-wild-type spartin or
Myc-mutant spartin PY/AA, which does not bind to
Figure 1 Atrophin-1-interacting protein 4 (AIP4) does not ubiquitinate spartin. (a) HeLa cells were transfected with Myc-wild-type spartin
together with an empty vector (lane 1), hemagglutinin (HA)-ubiquitin (lane 2), HA-ubiquitin and Flag-AIP4 (lane 3), or HA-ubiquitin and Flag-
AIP4C830A (lane 4). TCL = total cell lysates. WB = western blot. An asterisk (*) indicates crossreactive proteins. Sizes of protein standards are
indicated to the left in kDa. (b) Immunoprecipitates of HA-wild-type, mutant PY/AA, or 211-666 fragments of spartin and Flag-ubiquitin analyzed
by immunoblotting with anti-Flag (upper panel) or anti-HA (lower panel) antibodies. (c) HeLa cells were transfected with Flag-AIP4 alone or
together with HA-wild-type spartin, HA-spartin PY/AA, or HA-spartin 211-666 fragment. Cell lysates were immunoprecipitated (IP) with anti-HA
antibodies and immunoblotted with anti-Flag (upper panel) or anti-HA (lower panel) antibodies. An asterisk (*) and kDa are indicated as in A.
(d) Schematic diagram of spartin constructs and their status of ubiquitination and binding to AIP4.
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Page 3 of 11Figure 2 Spartin recruits atrophin-1-interacting protein 4 (AIP4) to lipid droplets. (a) HeLa cells were transfected with hemagglutinin (HA)-
spartin and immunostained for HA in blue (A1) and stained for lipid droplets with Bodipy 493/503 in green (A3). Merged image is shown in A4.
The boxed areas are enlarged in the insets. (b) HeLa cells were transfected with Flag-AIP4 and immunostained for Flag in red (B2) and stained
for lipid droplets with Bodipy 493/503 in green (B3). Merged image is shown in B4. The boxed areas are enlarged in the insets. (c) HeLa cells
were cotransfected with HA-spartin and Flag-AIP4 and immunostained for HA in blue (C1), for Flag in red (C2), and for lipid droplets with Bodipy
493/503 in green (C3). Merged image is shown in C4. The boxed areas are enlarged in the insets. (d) HeLa cells were cotransfected with HA-
spartin PY/AA and Flag-AIP4 and immunostained for HA in blue (D1), for Flag in red (D2), and for lipid droplets with Bodipy 493/503 in green
(D3). Merged image is shown in D4. The boxed areas are enlarged in the insets. Bars = 20 μm. (e) Colocalization of indicated expressed proteins
with lipid droplets was scored for 30 cells in each of 3 independent experiments. Transfected vectors are indicated with ‘+’ below each column.
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Page 4 of 11AIP4. In order to dissociate all proteins that could
potentially coprecipitate with AIP4, we boiled cell lysates
in SDS then decreased its concentration in lysate buffer.
We performed immunoprecipitation with anti-Flag anti-
bodies and immunoblotted the membrane with anti-HA
antibodies to detect ubiquitinated Flag-AIP4. As shown
in Figure 3a, the level of Flag-AIP4 ubiquitination
(represented by a high molecular weight smear of HA-
ubiquitin) was significantly higher in cells cotransfected
with wild-type spartin than in cells cotransfected with
mutant spartin that does not bind AIP4.
Furthermore, we examined whether binding of wild-
type spartin to AIP4 in vitro also results in increased
self-ubiquitination of AIP4. We investigated the levels of
self-ubiquitination of the glutathione S-transferase
(GST)-AIP4ΔC 2p r o t e i ni nt h ea b s e n c eo fs p a r t i no ri n
the presence of spartin fragments 155-367 or 155-367
PY/AA. We used these spartin fragments because they
are easily expressed in bacteria. We used AIP4 lacking
the C2 domain because this protein contains all neces-
sary domains for its autoinhibition and is well expressed
in bacteria [11]. As shown in Figure 3b (lane 2), in the
absence of spartin, AIP4ΔC2 was self-ubiquitinated at
low levels in the presence of all necessary components
for in vitro ubiquitination. When spartin 155-367 was
added to the reaction, self-ubiquitination of AIP4ΔC2
increased significantly as detected by anti-ubiquitin anti-
bodies (Figure 3b, lane 3, top panel). In the presence of
spartin, a high molecular weight smear was also
detected when we used anti-ITCH antibodies
(Figure 3b, lane 3, second panel from the top). In con-
trast, in the presence of mutant spartin 155-367 PY/AA,
AIP4ΔC2 was ubiquitinated at the same low levels as in
the absence of spartin (Figure 3b, lanes 4 and 2, respec-
tively). The results from in vitro and in vivo ubiquitina-
tion experiments demonstrate that spartin’sb i n d i n gt o
AIP4 significantly increases the catalytic activity of this
E3 ligase.
Spartin promotes polyubiquitination of adipophilin on
lipid droplets
Although spartin is not ubiquitinated by AIP4, by
recruiting AIP4 to lipid droplets and increasing its
activity, spartin might place AIP4 in the vicinity of its
substrate(s). One of those substrates might be adipo-
philin, also known as adipose differentiation-related
protein (ADRP), which has been shown to be polyubi-
quitinated [13]. To examine the levels of ubiquitination
of adipophilin in the absence of AIP4, AIP5, and AIP2,
we did not attempt to knock down AIP4, AIP5, and
AIP2 simultaneously in cells because depletion of two
of these E3 ubiquitin ligases results in cell death [14].
Using immunofluorescence, we determined that spartin
colocalizes with HA-adipophilin on lipid droplets
(Additional file 2). Thus, we tested whether spartin-
mediated recruitment of Nedd4 E3 ubiquitin ligases to
lipid droplets might be responsible for the polyubiqui-
tination of adipophilin. We found that spartin cells
treated with small interfering RNA (siRNA) showed
significantly less polyubiquitination of adipophilin
compared with control siRNA-treated cells (Figure 3c).
This suggests that spartin-mediated recruitment of
Nedd4 E3 ligases to lipid droplets might be responsible
for ubiquitination of adipophilin in HeLa cells.
Binding of spartin to AIP4 disrupts the proline-rich region
(PRR)/WW-HECT complex
Other researchers have suggested that the enzymatic
activity of AIP4 is autoinhibited by the intramolecular
interaction of its HECT domain with the region between
the proline-rich region and the WWIV domain [11,12].
Furthermore, we showed that spartin-mediated binding
to AIP4 increases its self-ubiquitination, implying that
spartin releases AIP4 from its autoinhibited state. To
assess the inhibitory interactions of AIP4 directly, we
purified the PRR/WWI-IV region and the HECT
domain of AIP4 and used the intermolecular PRR/WW-
HECT complex to mimic the autoinhibited state of
AIP4; then we examined whether spartin’sb i n d i n gt o
AIP4 disrupts this complex. We sought to quantitatively
measure the binding affinity between the PRR/WWI-IV
region and the HECT domain of AIP4.
By using a capture enzyme-linked immunosorbent
assay (ELISA), we detected saturable binding between
the proline-rich region (PRR)/WWI-IV region and the
HECT domain; the dissociation constant was 2 ± 0.4
μM (Figure 4a). We also observed saturable binding
between spartin and the PRR/WWI-IV region. The cal-
culated dissociation constant of this interaction was
0.34 ± 0.05 μM (Figure 4b). These results indicate that
spartin has a seven times higher affinity of binding to
the PRR/WWI-IV region than the binding of the PRR/
WWI-IV region has to the HECT domain. We assessed
whether the binding of spartin to AIP4 would disrupt
the PRR/WW-HECT complex, which would release
AIP4 from its autoinhibited state. As shown in Figure
4c, wild-type spartin inhibited the intermolecular inter-
action between HECT and the PRR/WWI-IV fragment
in a dose-dependent manner, with a half maximal inhi-
bitory concentration (IC50)o f0 . 5 6±0 . 0 8μMa n da n
inhibition constant of 0.21 ± 0.03 μM. In contrast,
mutant spartin PA/PY failed to inhibit the HECT-PRR/
WWI-IV complex. Thus, spartin increases enzymatic
activity of AIP4 indirectly by disrupting its PRR/WW-
HECT complex releasing AIP4 from it autoinhibited
state.
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Page 5 of 11Figure 3 Spartin increases activity of atrophin-1-interacting protein 4 (AIP4) and promotes ubiquitination of adipophilin. (a) HeLa cells
were cotransfected with Myc-wild-type spartin together with hemagglutinin (HA)-ubiquitin and an empty vector (lane 1), or Flag-AIP4 (lane 2),
or Myc-spartin PY/AA with HA-ubiquitin and Flag-AIP4 (lane 3). Cell lysates were boiled in sodium dodecyl sulfate (SDS) before
immunoprecipitation (IP) with anti-Flag antibodies. Levels of HA-ubiquitin and Flag-AIP4 in immunoprecipitates and total cell lysates (TCL) were
analyzed by immunoblotting. (b) Levels of in vitro ubiquitination assay of glutathione S-transferase (GST)-AIP4ΔC2 alone (lane 2), with
spartin155-367 (lane 3), or mutant spartin 155-367PY/AA (lane 4) determined by immunoblot with anti-ubiquitin antibodies (upper panel). All
reactions (except lane 1) were carried out in the presence of E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, ATP, and
ubiquitin. Coomassie blue stained gel (bottom panel). (c) In vivo ubiquitination assay of HA-adipophilin, also known as adipose differentiation-
related protein (ADRP) in HeLa cells transfected with either HA-empty vector or HA-ADRP, and control or spartin small interfering RNA (siRNA)
and Flag-ubiquitin and treated with 300 μM of oleic acid. Cell lysates were immunoprecipitated with anti-HA antibodies and immunoblotted
with anti-Flag or anti-HA antibodies.
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Hereditary spastic paraplegias, such as Troyer syndrome,
are neurodegenerative diseases characterized by progres-
sive weakness and spasticity in the lower limbs [1]. A
nucleotide deletion (1110delA) in spartin (SPG20)
causes autosomal recessive Troyer syndrome [2]. Pre-
viously, we demonstrated that this mutation results in a
complete loss of spartin and postulated that Troyer
syndrome has a loss-of-function disease mechanism [3].
Recently, it has been shown that spartin is involved
in turnover of lipid droplets by an unknown mechan-
ism [5]. These findings suggested that there is a link
between lipid droplet turnover and the pathology of
Troyer syndrome. In the present studies, we investi-
gated a molecular mechanism for spartin-dependent
regulation of lipid droplet turnover. This novel path-
way, which we call SPAA, involves spartin, the E3 ubi-
quitin ligase AIP4, and a major lipid droplet protein,
adipophilin.
Our study provides molecular and biochemical evi-
dence that spartin is not ubiquitinated by AIP4 but acts
as an adaptor protein for this E3 ubiquitin ligase. We
determined that spartin markedly increases self-ubiquiti-
nation of AIP4 through PPAY-mediated binding and
recruits it to the lipid droplets. We also demonstrated
that spartin promotes ubiquitination of adipophilin, a
lipid-associated protein that is known to affect triacyl-
glycerol turnover [15].
The catalytic activity of AIP4, similar to other
E3 ligases in the Nedd4 family [16], is regulated by
Figure 4 Binding of proline-rich region (PRR)/WWI-IV to the homologues of the E6-associated protein C-terminus (HECT) domain of
atrophin-1-interacting protein 4 (AIP4) and wild-type (WT) spartin. (a) Binding isotherm of the glutathione S-transferase (GST)-HECT protein
to PRR/WWI-IV. AU = arbitrary units. (b) Binding isotherm of the GST-WT spartin 155-367 protein to PRR/WWI-IV. (c) Inhibition of GST-HECT
binding to PRR/WWI-IV by WT spartin. All experiments were repeated three times. Data are shown as mean ± SD with an R
2 ≥ 0.95.
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Page 7 of 11intramolecular and intermolecular interactions. The
intramolecular interactions lead to the autoinhibition of
the catalytic activity of many members of the Nedd4
family E3 ligases [11,16]. It has been shown that autoin-
hibition of AIP4 is due to the binding between its
HECT domain and WW domains [12] or its HECT
domain and a sequence between the PRR and the WW
domains [11]. The current model that explains the
increase of AIP4 activity involves disrupting intramole-
cular binding within AIP4, which releases the HECT
domain from autoinhibition. We tested this model and
demonstrated quantitatively that PPAY-mediated bind-
ing of spartin to AIP4 disrupts the interaction between
the HECT domain and the PRR/WW region of AIP4.
The binding affinity of the PRR/WW region for spartin
(Kd =0 . 3μM) is about seven times stronger than the
binding affinity for the HECT domain (Kd =2μM) in
vitro. These data strongly support our model in which a
tight interaction between spartin and the WW-I and
WW-II domains of AIP4 (Additional file 3) disrupts a
weaker intramolecular interaction, which leads to
increased catalytic activity oft h i sE 3l i g a s e( F i g u r e5 ) .
Spartin interacts with other E3 ligases belonging to the
Nedd4 family, including AIP2 and AIP5 [5,8], which are
known to have a propensity for autoinhibition [11].
Therefore, we anticipate that spartin might also instigate
the enzymatic activity of these other E3 ubiquitin ligases
and will investigate them in future studies.
We have shown that spartin, through its PPAY motif,
sequesters AIP2 and AIP4 to endogenous lipid droplets.
This finding contrasts with that of previous studies that
showed decreased accumulation of YFP-spartin on lipid
droplets (stimulated with 500 μM of oleic acid) by over-
expressed Cherry-AIP5 [5]. One possible explanation for
this discrepancy is that the induction of lipid droplets
with a high dose of oleic acid and the large fluorescence
tags fused to both spartin and AIP5 significantly altered
the dynamics of those proteins.
We demonstrated that spartin facilitates ubiquitination
of adipophilin, a lipid droplet-associated protein. It has
been shown that adipophilin is polyubiquitinated and
then degraded by a proteasome-dependent pathway [13].
Ubiquitination is one of the mechanisms by which the
stability of adipophilin is regulated [13], and its level of
ubiquitination seems to be regulated by spartin-
mediated recruitment of Nedd4 E3 ubiquitin ligases to
lipid droplets (Figure 5). Because adipophilin decreases
triacylglycerol turnover [15,17], we propose that spartin
affects lipid droplet turnover ([5], and this study) (Addi-
tional file 4) by regulating the level of ubiquitination of
adipophilin and perhaps other lipid droplet-associated
proteins. We call this molecular mechanism the SPAA
pathway for lipid droplet turnover.
Impaired lipid droplet metabolism might be one of the
mechanisms in the pathogenesis of Troyer syndrome.
Malfunction of proteins involved in lipid maintenance is
considered to be a cause of some neurological disorders
[18]. For example, an autosomal-dominant hereditary
spastic paraplegia, HSP17, which is characterized by
muscle weakness in upper limbs and spasticity of lower
limbs, is caused by a mutation in the Berardinelli-Seip
congenital lipodystrophy 2 (BSCL2) gene encoding sei-
pin [19]. Seipin has been shown to maintain the physio-
logical morphology and size of lipid droplets in yeast
[20]. A large number of lipid droplets in atrophic a
motor neurons have been reported in hereditary porcine
neuronal degeneration [21]. Now, based on the SPAA
pathway for lipid droplet turnover, we can begin unra-
veling the specific biological role of spartin in Troyer
syndrome.
Figure 5 Model of spartin’s role in the activation and recruitment of atrophin-1-interacting protein 4 (AIP4) to lipid droplets and
subsequent adipophilin ubiquitination. AIP4 in the absence of binding to spartin is in an autoinhibited conformation (left panel). Our
heuristic model predicts that spartin, via its PPAY motif, recruits AIP4 to lipid droplets and alters AIP4 conformation, which leads to its increased
enzymatic activity. The ubiquitination of resident proteins present on lipid droplets, such as adipophilin, is facilitated by the spartin-mediated
recruitment and activation of AIP4 (right panel). I, II, III, IV = WW-I, WW-II, WW-III, and WW-IV domains; ADRP = adipophilin (also known as
adipose differentiation-related protein); C2 = calcium binding domain; HECT = homologues of the E6-associated protein C-terminal domain;
LD = lipid droplet; PPAY = PPAY motif of spartin; PRR = proline-rich domain; Ub = ubiquitin.
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In summary, spartin is not a substrate for AIP4 E3 ubiqui-
tin ligase. Instead, spartin acts as a classic adaptor protein
that recruits AIP4 to lipid droplets and increases its enzy-
matic activity. In addition, spartin acts as a linker for ubi-
quitination of adipophilin on lipid droplets, likely by
sequestering Nedd 4 E3 ubiquitin ligases and ubiquitina-
tion machinery. These might be one of the mechanisms by
which spartin regulates lipid droplet turnover and which
may contribute to the pathophysiology of SPG20.
Methods
Antibodies and reagents
The following antibodies were used: rabbit polyclonal
anti-hemagglutinin (HA; Abcam, Cambridge, MA, USA),
mouse monoclonal anti-HA (12CA5; Covance, Prince-
ton, NJ, USA), rabbit polyclonal anti-Myc, mouse mono-
clonal anti-Flag conjugated to horseradish peroxidase
(HRP) (clone M2; Sigma, St. Louis, MO, USA), mouse
monoclonal anti-ITCH (BD Biosciences, San Jose, CA,
USA), mouse monoclonal anti-ubiquitin P4D1 (Cell Sig-
naling, Danvers, MA, USA), and rabbit polyclonal anti-
glutathione S-transferase (GST) (Santa Cruz, Santa
Cruz, CA, USA). The rabbit anti-spartin antibody was
used as described previously [22]. The anti-mouse and
anti-rabbit antibodies conjugated to HRP were from
Thermo Fischer Scientific (Waltham, MA, USA). Sec-
ondary goat anti-mouse and anti-rabbit Alexa Fluor
568-conjugated or 633-conjugated antibodies were from
Invitrogen (Carlsbad, CA, USA)
Mammalian expression vectors
The full-length human spartin cDNA in the pGW1-HA
and pGW1-Myc expression vectors have been described
previously [6]. Flag-AIP4 in a pCMV-10 vector was a
gift from Adriano Marchese (Loyola Chicago University,
Maywood, IL, USA). To generate the pGW1-HA spartin
211-666 construct, residues 211-666 of human spartin
were amplified by PCR using PfuTurbo (Agilent Tech-
nologies, Santa Clara, CA, USA) and cloned in frame
into an EcoRI site of the pGW1-HA vector. To generate
spartin PY172,174AA and Flag-AIP4C830A, site-directed
mutagenesis was applied using the QuickChange proto-
col (Agilent Technologies). We refer to mutant spartin
PY172,174AA as spartin PY/AA. HA-adipophilin was
obtained from GeneCopoeia (Rockville, MD, USA). The
Flag-AIP2 vector was a gift from Richard Longnecker
(Northwestern University, Evanston, IL, USA).
Bacterial expression vectors
The pGEX-4T2 with each WW domain I, II, III, IV
and pGEX-4T2 with HECT domain were gifts from
Adriano Marchese (Loyola Chicago University). A vector
expressing GST-AIP4ΔC2 was a gift from Annie Angers
(University of Montreal, Montreal, Canada). The
pGEX6p-1-PRR-WWI-IV (155-486) vector was gener-
ated by PCR using full-length AIP4 as a template. To
generate pGEX6p-1-wild-type spartin 155-367 or
pGEX6p-1-spartin 155-367 PY172,174AA, human spar-
tin was amplified by PCR using either wild-type or
mutant spartin cDNA as a template.
Cell culture and transfections
HeLa cells were maintained in Dulbecco’sm o d i f i e d
Eagle’s medium (Invitrogen) supplemented with 10%
fetal bovine serum (Gemini BioProducts, West Sacra-
mento, CA, USA). The transfections with plasmids or
plasmids together with control siRNA or spartin siRNA
[6] were performed using the TransIT-HeLaMONSTER
transfection kit (Mirus, Madison, WI, USA) and Lipofec-
tamine 2000 (Invitrogen), respectively.
Immunofluorescence
HeLa cells were grown on glass cover slips, transfected,
and processed as described previously [23]. Cover slips
were mounted with ProLong Antifade reagent (Invitro-
gen) and imaged using a Zeiss LSM-510 confocal micro-
s c o p e( Z e i s s ,M a p l eG r o v e ,M N )w i t ha6 3×1 . 4N A
Plan Apochromat oil immersion objective at 1024 ×
1024 resolution. The images were processed with Adobe
Photoshop 7.0 software (Adobe, San Jose, CA, USA).
Image analysis
For each specified immunofluorescence condition,
30 cells that showed overexpressed proteins were ana-
lyzed at random, and colocalization was assessed with
line scans using Zeiss software. A total of 90 cells were
analyzed in 3 independent experiments. The data are
represented as the percentage of cells that show coloca-
lization of immunostained, overexpressed proteins with
lipid droplets.
In vitro ubiquitination
The assays were conducted in reaction buffer with
reagents that were describedp r e v i o u s l y[ 1 1 ]a n dw i t h
1-2 μg of GST-AIP4ΔC2 alone or together with spartin
155-367 wild-type or spartin 155-367 PY172,174AA pro-
teins, both of which were cleaved of their GST tag by
using PreScission protease (GE Healthcare, Waukesha,
WI, USA). The samples were incubated for 60 min at
37°C and analyzed by immunoblotting using anti-ubiqui-
tin and anti-ITCH antibodies.
In vivo ubiquitination
Transfected HeLa cells were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed with buffer
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X-100, 10 mM N-ethylmaleimide, and protease inhibi-
tors. Cell lysates were denatured with 1% SDS, boiled
for 5 min, and diluted 14 times with lysis buffer to
lower the concentration of SDS before immunoprecipi-
tation. For in vitro ubiquitination of HA-ADRP in cells
treated with control or spartin siRNA, cells were treated
with 300 μM of oleic acid overnight and then subse-
quently with MG132 for 3 h.
ELISA
The following plasmids were used to express proteins in
b a c t e r i a :p G E X - 4 T 2 - H E C T ,p G E X 6 p - 1 - P R R - W W I - I V ,
pGEX6p-1-wild-type (WT) spartin 155-367, and
pGEX6p-1-spr 155-367 PY/AA. Proteins were purified
as described previously [24]. We applied PreScission
protease (GE Healthcare) to remove the N-terminal
GST tag from GST-PRR/WWI-IV, GST-WT spartin
155-367, and GST-spartin 155-367 PY/AA. All proteins
were dialyzed using PBS. ELISA microplates (96 well;
BD Biosciences) were coated with 50 ng of PRR/WWI-
IV per well in 10 mM phosphate buffer (pH 7.4) and
incubated overnight at 4°C. After washes and blocking,
serially diluted samples of GST-WT spartin 155-367,
GST-spartin 155-367 PY/AA, or GST-HECT were
added, and the plates were incubated for 2 h. The plates
were washed with PBS and then incubated for 1 h with
rabbit anti-GST. After the washes with PBS and 0.05%
Tween 20, the plates were incubated with a 1:1,000 dilu-
tion of anti-rabbit HRP conjugated antibodies for 1 h.
After washes with PBS, the color was developed with
3,3′5,5′-tetramethylbenzidine (Thermo Fisher Scientific)
for 5 min, and the optical density was read at 630 nm.
The assays were performed in triplicate. Prism 5
(Graphpad Software, La Jolla, CA, USA) was used to
analyze binding data. For competition ELISA, 5 μMo f
GST-HECT was incubated with serially diluted WT
spartin 155-367 or spartin 155-367 PY/AA in wells
coated with 50 ng of PRR/WWI-IV. The amount of
bound GST-HRP was detected using anti-GST
antibodies.
Analysis of ELISA data
The IC50 and Kd were calculated by fitting the data points
with either the one-site binding curve AU = AU0 ×
((GST-protein)/((GST-protein) + Kd) or the competitive
binding curve %GST-HECT-binding = Min + (Max -
Min)/(1 + 10
((WT spartin) - log(IC50))), where AU (AU0) is the
ELISA (maximal) absorption reading, (GST-protein) is
either the GST-HECT or GST-WT spartin 155-367 con-
centration, (WT spartin) is the WT spartin 155-367 con-
centration, and Min(Max) is the minimal (maximal)
percentage of GST-HECT binding. The inhibition
constant, Ki, was calculated by using the equation Ki =
IC50/(1 + (GST-HECT)/Kd) [25] based on an IC50, concen-
tration of bound GST-HECT, (GST-HECT) = 5 μM, and
GST-HECT binding affinity for PRR/WWI-IV, Kd =2μM.
Additional file 1: Additional figure 1. Spartin recruits atrophin-1-
interacting protein 2 (AIP2) to lipid droplets. (a) HeLa cells were transfected
with Flag-AIP2 and immunostained for Flag in red (A2), and lipid droplets
were stained with Bodipy 493/503 in green (A3). Merged image is shown in
A4. The boxed areas are enlarged in the insets. (b) HeLa cells were
cotransfected with hemagglutinin (HA)-spartin and Flag-AIP2 and stained
for HA in blue (B1), Flag in red (B2), and lipid droplets with Bodipy 493/503
in green (B3). Merged image is shown in B4. The boxed areas are enlarged
in the insets (c) HeLa cells were cotransfected with HA-spartin PY/AA and
Flag-AIP2 and stained for HA in blue (C1), Flag in red (C2), and for lipid
droplets with Bodipy 493/503 in green (C3). Merged image is shown in C4.
The boxed areas are enlarged in the insets. Bars = 20 μm. (d) Colocalization
of indicated expressed proteins with lipid droplets was scored for 30 cells in
each of 3 independent experiments. Transfected vectors are indicated with
‘+’ below each column.
Additional file 2: Additional figure 2. Spartin colocalizes with
adipophilin (also known as adipose differentiation-related protein (ADRP))
in lipid droplets. (a) HeLa cells were cotransfected with Myc-spartin and
hemagglutinin (HA)-ADRP and immunostained for Myc in blue (A1), HA
in red (A2), and stained for lipid droplets with Bodipy 493/503 in green
(A3). Merged image is shown in A4. (b) Colocalization of Myc-spartin and
HA-ADRP with lipid droplets was scored for 30 cells in each of 3
independent experiments. Transfected vectors are indicated with ‘+’
below each column.
Additional file 3: Additional figure 3. Spartin interacts with the WW-I
and WW-II domains of atrophin-1-interacting protein 4 (AIP4) in vitro.
Upper panel: Lysates from HeLa cells were transfected with
hemagglutinin (HA)-tagged wild-type spartin or HA-spartin PY/AA and
were incubated with glutathione S-transferase (GST) alone or GST-WW I-
IV of AIP4, or GST fused with each WW domain of AIP4. Bound proteins
from the precipitation assay were immunoblotted with anti-HA
antibodies. Lower panel: Coomassie blue stained gel.
Additional file 4: Additional figure 4. Depletion of spartin increases
the size and number of lipid droplets. (a) HeLa cells were treated with
control (A1) or spartin small interfering RNA (siRNA) (A2) for 48 h and
then incubated with 300 μM of oleic acid and stained for lipid droplets
using Bodipy 493/503. (b) The bars show the average number of lipid
droplets ± standard error in cells treated with control or spartin siRNA
from 3 independent experiments using 30 cells each. An asterisk (*)
represents significance at P < 0.01 calculated by Student t test.
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